Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocardial Function Response to Dobutamine in T2DM and Metabolic Syndrome
NCT02505451Completed
- Sponsor
- Avignon University
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dobutamine in type 2 diabetes mellitus (T2DM) and metabolic syndrome (3 arms), sponsored by Avignon University. Primary endpoint: Regional longitudinal strain at Day 1. Started Jul 2015; status: completed.
02
Drugs
dobutamine
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic syndrome
Beyond the preview
Go deeper on NCT02505451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505451.